Skip to content

CRBP

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ · USHealthcareBiotechnology
$8.89-1.33%

Price as of Jul 20, 2026

CRBP growth

Corbus Pharmaceuticals Holdings, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
EBITDA
-67.4%
EBIT
-52.6%
EPS
+3.9%
Free cash flow
-46.6%
Operating cash flow
-46.6%

Forward estimates

Revenue
EBITDA
EPS
+17.3%

Three-year CAGR

Revenue
EBITDA
EBIT
-75.1%
Net income
-95.3%
EPS
-60.3%
Free cash flow
-54.3%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.